Merck sells eye business

Share this article:

First Merck sold its consumer business to Bayer. Now, it's also (almost) getting out of the eye-care business. The company announced Tuesday that it has sold part of the business to Santen Pharmaceutical.

The $600-million-plus-milestones deal includes rights to the eye products Cosop, Trusop and Timoptic in Japan and “key markets in Europe and Asia Pacific.” Merck said the sales for these products in these territories is around $400 million a year.

Merck will continue to sell these products in Latin America, Canada and Australia, but sold US rights to Akorn in 2013 and 2014.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

DOJ closes Brilinta investigation

AstraZeneca announced the end of the investigation Tuesday.

Doctors back unique biosimilar names

A host of doctors has asked FDA Commissioner Margaret Hamburg to back a naming convention that would require biologics and biosimilars to have different names.

Roche has no rights to Sovaldi, panel rules

Despite a collaboration with original Sovaldi owner Pharmasset in 2004, a panel ruled Roche has no rights to HCV treatment Sovaldi.